News

(WASHINGTON, D.C.) – Representatives from the Consumer Healthcare Products Association (CHPA), Sanofi Consumer Healthcare, Haleon, Kenvue, and Bayer participated in a discussion this week hosted by U.S. Rep. Bob Latta (OH-05) to provide an analysis of the over-the-counter (OTC) Monograph Drug User Fee Program (OMUFA), how some OTCs come to market through the Rx-to-OTC-switch process, how these products are regulated by the U.S. Food and Drug Administration (FDA), and industry’s efforts to expand HSA/FSA coverage for dietary supplements and oral care products.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) today announced the appointment of Michael A. Bailey to serve as its new Senior Vice President of Regulatory & Scientific Affairs. Having nearly four decades of extensive scientific and regulatory affairs experience at leading healthcare companies, Bailey will bring a diverse wealth of knowledge and expertise to CHPA’s regulatory department. He will officially begin his work at CHPA on April 15, 2024. Bailey will report to CHPA President and CEO Scott Melville and will be a member of the association’s senior management team.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following the adoption of Kentucky House Bill 386 into law, legislation that will eliminate the state’s annual purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE), which is currently the most restrictive yearly limit nationwide at 24 grams, or roughly a three-month supply.